Ignite Creation Date:
2024-05-06 @ 10:14 AM
Last Modification Date:
2024-10-26 @ 12:27 PM
Study NCT ID:
NCT03204370
Status:
RECRUITING
Last Update Posted:
2023-07-21
First Post:
2017-06-07
Brief Title:
Natural History of Atypical Morquio A Disease
Sponsor:
GOIZET
Organization:
Association Aquitaine de Recherche Clinique en Rhumatologie
Study Overview
Official Title:
Natural History of Atypical Morquio A Disease a 5-years Prospective Study in a Series of 9 Adult Patients Followed in a Single Expert Center
Status:
RECRUITING
Status Verified Date:
2024-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Mucopolysaccharidosis IVA MPS IVA or Morquio A disease is a rare recessive autosomal lysosomal storage disorder caused by deficiency of N-acetylgalactosamine-6-sulfatase GALNS resulting in accumulation of the glycosaminoglycans GAGs chondroitin-6-sulfate and keratin sulfate KS Patients display progressive development of skeletal and joint abnormalities and non-skeletal features including respiratory cardiac sensorial and neurological complications Recently a specific treatment using enzyme replacement therapy ERT with recombinant human GALNS elosulfase alfa has become available A multicenter double-blind placebo-controlled phase 3 trial 176 patients age 5 yrs showed significant improvement in endurance of 225 m in 6 Minute Walking Test 6MWT distance after 24 weeks of treatment with elosulfase alfa at 20 mgkgweek as compared with placebo group In addition to ERT a multidisciplinary management approach is necessary for coordinating assessment and follow-up as well as for providing individualized supportive and symptomatic care
The clinical presentation is highly variable from one patient to another regarding age at onset severity progression rate and life expectancy Most patients are affected with the classical phenotype characterized by short trunk dwarfism with short neck and adult height 1 m Atypical phenotypes with less severe extension of skeletal manifestations adult height 1m and less frequent complications in other organs have been progressively recognized Clinical management differs depending on the clinical presentation of the patients but natural history of the disease is largely unknown in atypical phenotypes Precise and exhaustive follow-up data are needed in such patients to increase our knowledge of this natural history and to define the best criteria to evaluate ERT efficiency
The investigators propose a prospective clinical study focused on a unique large series of 9 adult patients aged from 18 to 55 years followed in a single expert center for metabolic disorders located at the university hospital of Bordeaux France Eight of these patients are affected with atypical MPS IVA characterized by less severe evolution of the disease and heights ranging from 135 to 176 cm the last patient height is 102 cm Investigators aim to increase knowledge on the natural history of the disease in adult patients with atypical MPS IVA treated or not with ERT and to develop new objective and robust clinical criteria to evaluate the efficiency of ERT over time particularly in patients presenting an atypical phenotype The entire cohort treated or not treated with ERT will be evaluated at baseline and every year during a 5-years period The complete evaluation at baseline will be our absolute priority as well as obtaining long-term and exhaustive follow up of the patients treated with ERT two patients of the cohort already treated and ERT expected in three additional patients in the next months
The investigators designed a schedule of systematic and exhaustive assessments based on the recommended follow up from experts panel consensus meeting MorCAP protocol extended to some additional investigations including motor cardiac and rheumatologic exams as our specific focus
The clinical presentation is highly variable from one patient to another regarding age at onset severity progression rate and life expectancy Most patients are affected with the classical phenotype characterized by short trunk dwarfism with short neck and adult height 1 m Atypical phenotypes with less severe extension of skeletal manifestations adult height 1m and less frequent complications in other organs have been progressively recognized Clinical management differs depending on the clinical presentation of the patients but natural history of the disease is largely unknown in atypical phenotypes Precise and exhaustive follow-up data are needed in such patients to increase our knowledge of this natural history and to define the best criteria to evaluate ERT efficiency
The investigators propose a prospective clinical study focused on a unique large series of 9 adult patients aged from 18 to 55 years followed in a single expert center for metabolic disorders located at the university hospital of Bordeaux France Eight of these patients are affected with atypical MPS IVA characterized by less severe evolution of the disease and heights ranging from 135 to 176 cm the last patient height is 102 cm Investigators aim to increase knowledge on the natural history of the disease in adult patients with atypical MPS IVA treated or not with ERT and to develop new objective and robust clinical criteria to evaluate the efficiency of ERT over time particularly in patients presenting an atypical phenotype The entire cohort treated or not treated with ERT will be evaluated at baseline and every year during a 5-years period The complete evaluation at baseline will be our absolute priority as well as obtaining long-term and exhaustive follow up of the patients treated with ERT two patients of the cohort already treated and ERT expected in three additional patients in the next months
The investigators designed a schedule of systematic and exhaustive assessments based on the recommended follow up from experts panel consensus meeting MorCAP protocol extended to some additional investigations including motor cardiac and rheumatologic exams as our specific focus
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None